MOUNJARO® (Tirzepatide)

Mounjaro® is also used for weight loss when clinically appropriate

Mounjaro® (tirzepatide) is an injectable medication administered once weekly to enhance blood sugar control and aid in weight loss for individuals with type 2 diabetes. Similar to other GLP-1 medications used for type 2 diabetes such as Trulicity® and Ozempic®, Mounjaro® (tirzepatide) contains the GLP-1 compound.

Additionally, Mounjaro® (tirzepatide) contains a second compound known as Glucose-dependent Insulinotropic Polypeptide (GIP). The combination of two compounds in Mounjaro® (tirzepatide) has proven to be highly effective in controlling glucose levels in individuals with type 2 diabetes. Additionally, it has demonstrated substantial efficacy in aiding individuals with overweight and obesity to achieve significant weight loss. In many cases, Mounjaro® (tirzepatide) has also been effective in preventing diabetes in patients with prediabetes. Mounjaro® is manufactured by Eli-Lilly and was FDA-approved for type 2 diabetes in May of 2022.

Mounjaro® (tirzepatide) functions similarly to other drugs in the GLP-1 family, but it includes an additional compound known as Glucose-dependent Insulinotropic Polypeptide (GIP). Therefore, Mounjaro® (tirzepatide) imitates the actions of two incretin hormones involved in blood sugar regulation: Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP). This combined mode of action makes it the first FDA-approved diabetes medication to target both receptors.

You are eligible to take Mounjaro® (tirzepatide) if you are 18 years old with a diagnosis of Type 2 Diabetes.

Additionally, you are eligible to use Mounjaro® (tirzepatide) for weight loss if you are 18 years old or over and meet the following criteria:

1. BMI of 30 or more.
2. BMI of 27 or more with related health problems such as type 2 diabetes, high cholesterol, high blood pressure, heart disease, fatty liver, sleep apnea or prediabetes.
3. No personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
4. No history of pancreatitis.

According to a landmark study (SURMOUNT-1) published in November of 2024, “Individuals treated with tirzepatide lost on average up to 23% of their body weight and maintained this for over three years, while benefitting from a substantial decrease in risk of developing type 2 diabetes.”

In addition, in patients with type 2 diabetes, Mounjaro® (tirzepatide) has been shown to reduce A1c by as much as 2.4% at the 15mg dose.

At Worthy Weight Loss in Plano, Texas, patients who have been prescribed Mounjaro® (tirzepatide) in conjunction with a lifestyle modification regimen (including diet and exercise), have demonstrated a weight loss of up to 30%.